Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kanitinib in recurrent or metastatic solid tumors
NCT02916095Phase 1Completed
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Nov 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of kanitinib in solid tumor, sponsored by Beijing Konruns Pharmaceutical Co., Ltd. Primary endpoints: Adverse events assessment, changes of physical signs, laboratory examination and 12-lead electrocardiogram at 2 years and Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) at 2 years. Started Nov 2016; status: completed.
02
Drugs
kanitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02916095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916095.